Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate whether the addition of the Src inhibitor
saracatinib (AZD0530) to weekly paclitaxel improves efficacy, compared with paclitaxel plus
placebo, in patients with relapsed platinum-resistant ovarian cancer. The trial will also
determine toxicity and ascertain whether the combination of paclitaxel plus saracatinib
should proceed to a phase III trial.